Literature DB >> 16002843

Molecular markers of early pancreatic cancer.

Michael Goggins1.   

Abstract

Pancreatic cancer is a deadly disease and the fourth most common cause of cancer death in the United States. Since chemotherapy and radiotherapy have thus far largely failed to significantly improve the survival of patients with pancreatic ductal adenocarcinoma, there is considerable interest in identifying better diagnostic markers of pancreatic neoplasia. Not only could better markers improve the early diagnosis of pancreatic cancer and allow more patients to undergo curative surgical resection, but also could potentially be used for patients at high risk of developing pancreatic cancer to identify precancerous lesions while they are amenable to cure. A wealth of information has recently become available about gene expression, DNA methylation, and proteomics alterations that occur in pancreatic cancers creating hope that better diagnostic markers of pancreatic cancer will be soon forthcoming.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002843     DOI: 10.1200/JCO.2005.19.711

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  73 in total

Review 1.  Circulating tumor cells in the diagnosis and management of pancreatic cancer.

Authors:  Putao Cen; Xiaoling Ni; Jingxuan Yang; David Y Graham; Min Li
Journal:  Biochim Biophys Acta       Date:  2012-06-07

2.  Significance of microRNA-based biomarkers for pancreatic cancer.

Authors:  Sukhwinder Kaur; Shiv Ram Krishn; Satyanarayana Rachagani; Surinder K Batra
Journal:  Ann Transl Med       Date:  2015-10

3.  A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.

Authors:  Jill P Smith; John F Harms; Gail L Matters; Christopher O McGovern; Francesca M Ruggiero; Jiangang Liao; Kristin K Fino; Emily E Ortega; Evan L Gilius; John A Phillips
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

Review 4.  [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].

Authors:  J M Löhr; R Faissner; P Findeisen; M Neumaier
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

Review 5.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

6.  Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.

Authors:  Jiangning Gu; Di Wang; Ya Huang; Yi Lu; Chenghong Peng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 7.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

8.  DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease.

Authors:  Mansour A Parsi; Ang Li; Chung-Pin Li; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-05       Impact factor: 11.382

9.  CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Ji-Cong Gui; Wei-Li Yan; Xing-Dang Liu
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

10.  Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

Authors:  Stephanie T Chang; Jacob M Zahn; Joe Horecka; Pamela L Kunz; James M Ford; George A Fisher; Quynh T Le; Daniel T Chang; Hanlee Ji; Albert C Koong
Journal:  J Transl Med       Date:  2009-12-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.